Monitor upcoming Q3 2026 full financial filing for EPS, operating expenses, and cash position. Sequential revenue growth trajectory and margin expansion are key to the profitability-in-2027 narrative; any deviation will move the stock.
Price Chart
Executive Summary
Scienture Holdings reported preliminary Q3 2026 revenue of ~$1.22M, up 256% sequentially from Q2's $344K, driven by Arbli growth and the REZENOPY launch. EPS of -$1.75 missed the consensus estimate of -$1.50 by 16.7%, though the company highlighted high gross margins (~97.7%) and a path to profitability in 2027. The sequential revenue acceleration and removal of Nasdaq delisting risk (per the cross-filing) are positive, but the EPS miss and early-stage commercial scale temper the outlook.
Key Financial Metrics
Key Facts
- Preliminary Q3 2026 revenue of ~$1.22M, up 256% sequentially from $343,639 in Q2 2026.
- EPS of -$1.75 missed consensus estimate of -$1.50 by 16.7%.
- Arbli wholesale unit sales increased 74% sequentially in Q3 2026.
- REZENOPY commercially launched in August 2026, contributed initial wholesale shipments to Q3 revenue.
- Gross margins of ~97.7% reported in Q2 2026 (most recent available).
- Operating expenses decreased ~41% YoY to $3.0M in Q2 2026; net loss narrowed ~58% to $2.8M.
- Company targets profitability in 2027.
- Nasdaq confirmed compliance with $1.00 minimum bid price rule (per cross-filing).
Financial Impact
Revenue of ~$1.22M (256% sequential growth); EPS miss of -$1.75 vs -$1.50 consensus; gross margins ~97.7%
Risk Factors
- EPS miss of 16.7% signals ongoing operating losses despite revenue growth.
- Revenue base remains very small (~$1.22M quarterly); profitability in 2027 depends on sustained high growth.
- Dependence on two recently launched products with limited commercial track record.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3386312 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $2.77 | awaiting T+5 | — | $3.23 (+16.61%) |
Oct 19, 2026 8d ago | 8-K | $3.05 $3.23 | ▲ +5.90% | ▲ +5.82% | $3.23 (+5.90%) |
Oct 13, 2026 14d ago | Press Release | $3.24 $3.05 | ▲ +5.86% | ▲ +4.71% | $3.23 (+0.31%) |
Oct 7, 2026 20d ago | 8-K | $3.86 $3.38 | ▼ −12.44% | ▼ −12.16% | $3.23 (−16.32%) |
May 29, 2026 21w ago | 8-K | $0.3960 $0.3600 | ▼ −9.09% | ▼ −6.34% | $3.23 (+715.66%) |
May 22, 2026 22w ago | 8-K | $0.4000 $0.3910 | ▼ −2.25% | ▼ −3.46% | $3.23 (+707.50%) |
May 18, 2026 23w ago | Press Release | $0.3940 $0.4000 | ▲ +1.52% | ▼ −0.10% | $3.23 (+719.80%) |
May 5, 2026 25w ago | 8-K | $0.3910 $0.3980 | ▲ +1.79% | ▲ +0.66% | $3.23 (+726.09%) |
Apr 30, 2026 25w ago | 10-K/A | $0.4010 $0.4000 | ▲ +0.25% | ▲ +2.60% | $3.23 (−705.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers